{"prompt": "['The VWDMin Trial', 'Version v1.0', 'Protocol PRO15070638', 'March 19, 2018', '11 REFERENCES', '1.', 'Rodeghiero F, Castaman G, Dini E. Epidemiologic investigation of the prevalence of von Willebrand', 'disease. Blood 1987; 69: 454-9.', '2.', 'Sadler JE, Budde U, Eikenboom JCJ. Update on the pathophysiology and classification of von', 'Wilebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost', '2006; 4: 2103-14.', '3.', 'Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, Rick ME,', 'Sadler JE, Weinstein M, Yawn BP. Von Willebrand Disease (VWD): Evidence-based diagnosis and', 'management guidelines, the National Heart Lung and Blood Institute (NHLBI) Expert Panel', 'Report', '(USA). Haemophilia 2008; 14: 171-232.', '4.', 'Ragni MV, Bontempo FA, Cortese-Hassett AL. von Willebrand disease and bleeding in women.', 'Haemophilia 1999; 5: 313-7.', '5.', 'James A, Ragni MV, Picozzi V. ASH Special Educational Symposium: Bleeding Disorders in', 'Premenopausal Women: Another Public Health Crisis for Hematology. Hematology 2006; 474-85.', '6.', 'James AH. Women and bleeding disorders. Haemophilia 2010; 16 (Suppl 5): 160-7.', '7.', 'Byams VR, Baker J, Brown DL, Gill JC, Grant AM, James AH, Konkle BA, Kulkarni R, Maahs J, Malone', 'M, McAlister SO, Nugent D, Philipp CS, Soucie JM, Stang E, Kouides PA. Baseline characteristics of', 'females with bleeding disorders receiving care in the U.S. HTC Network. National Conference on', 'Blood Disorders in Public Health 2010; E3: 3 (abstract).', '8.', 'Mannucci PM, Kempton C, Miller C, Romond E, Shapiro A, Birschmann I, Ragni MV, Gill JC, Yee', 'TT, Klamroth R, Wong WY, Chapman M, Engl W, Turecek PL, Suiter TM, Ewenstein BM.', 'Pharmokinetics and safety of a novel recombinant human von Willebrand factor manufactured', 'with a plasma-free method: a multicenter prospective clinical trial. Blood 2013; 122:648-57.', '9.', 'Gill J, Castaman G, Windyga J, Kouides P, Ragni M, Leebeek F, Obermann-Slupetzky, Chapman M,', 'Fritsch S, Pavlova BG, Presch I, Ewenstein B. Safety, efficacy, and pharmacokinetics of a', 'recombinant von Willebrand factor in patients with severe von Willebrand disease. Blood 2015;', '126: 2038-46.', '10.', 'Machin N, Ragni MV, Malec L, Brambilla D, Coyle T, Davis J, Drygalski A, James A, Jobe S, Kessler', 'C, Konkle B, Kouides P, Kuriakose P, Ma A, Majerus E, Nance D, Neff A, Philipp C, Weng TF, Haish', 'H. Von Willebrand Factor for menorrhagia: A Survey and Literature Review. American Society of', 'Hematology, Orlando FL, Blood 2015; 126: 4694.', '11.', 'Ragni MV, Machin N, Malec L, James A, Konkle B, Kouides P, Neff A, Philipp C, Brambilla D. Von', 'Willebrand factor for menorrhagia: Survey and Literature Review. Haemophilia 2016; 22: 397-', '402.', '12.', 'Abshire TC, Federici AB, Alvarez MT, BowenJ, Carcao MD, Gill JC, Key NS, Kouides PA, Kurnik K, Lail', 'AE, Leebeek FWG, Makris M, Mannucci PM, Winikoff R, Berntorp E. Haemophilia 2013; 19: 76-81.', '13.', 'Batty P, Chen YH, Bowles L, Hart DP, Platton S, Pasi KJ. Safety and efficacy of a von Willebrand', 'factor/factor VIII concentrate (Wilate): a single centre experience. Haemophilia 2014; 20: 846-', '53.', '14.', 'Berntorp E, Windyga J, and The European Wilate Study Group. Treatment and prevention of acute', 'bleedings in von Willebrand disease - efficacy and safety of Wilate, a new generation von', 'Willebran factor/factor VIII. Haemophilia 2009; 15: 122-30.', '15.', 'Holm E, Abshire TC, Bowen J, Alvarez MT, Bolton-Maggs P, Carcao M, Federici AB, Gill JC, Halijmeh', 'S, Kempton C, Key NS, Kouides P, Lail A, Landorph A, Leebeek F, Makris M, Mannucci P, Mauser-', 'Bunschoten EP, Nugent D, Valentino LA, Winikoff R, Berntorp E. Changes in bleeding patterns in', '52']['The VWDMin Trial', 'Version v1.0', 'Protocol PRO15070638', 'March 19, 2018', 'von Willebrand disease after institution of long-term replacement therapy: results from the von', 'Willebrand Disease Prophylaxis network. Blood Coag Fibrinolysis 2015; 26: 383-8.', '16.', 'Miesbach W, Krekeler S, Wolf Z, Seifried E. Clinical use of Haemate P in von Willebrand disease:', 'A 25-year retrospective observational study. Thromb Res 2014; 135: 479-84.', '17.', 'National Institute for Health and Clinical Excellence. NICE Clinical guidelines 44: heavy menstrual', 'bleeding. London (UK): National Health Service, 2007.', '18.', 'Kadir RA, Edlund M, von Mackensen S. The impact of menstrual disorders on quality of life in', 'women with inherited bleeding disorders. Haemophilia 2010; 16: 832-9.', '19.', 'Hallberg L, Milsson L. Determinants of menstrual blood loss. Scand J Lab Invest 1996; 16: 244-8.', '20.', 'Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Frequency of inherited bleeding disorders', 'in women with menorrhagia. Lancet 1998; 351: 485-9.', '21.', 'Vessey MP, Villard-Mackiontosh L, McPherson K, Coulter A, Yeates D. The epidemiology of', 'hysterectomy: findings in a large cohort study. Br J Obst Gynaecol 1992; 99: 402-7.', '22.', 'Doherty L, Harper A, Russell M. Menorrhagia management options. Ulster Med J.1995; 64: 64-71.', '23.', 'ACOG. Management of Anovulatory Bleeding. Washington, DC: American College of Obstetricians', 'and Gynecologists, 2000.', '24.', \"Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br\", 'J Haematol 1990; 97: 734-9.', '25.', 'Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a pictorial chart: a validation', 'study. BJOG 2000; 107: 320-2.', '26.', 'Ragni MV, Jankowitz RC, Merricks EP, Kloos M, Nichols TM. Recombinant interleukin-1', '(Neumega) in women with von Willebrand disease and menorrhagia. Thromb Haemost 2011;', '106: 641-5.', '27.', 'Kouides PA, Byams VR, Philipp CS, Stein SF, Heit JA, Lukes AS, Skerrette NI, Dowling NF, Evatt BL,', 'Miller CH, Owens S, Kulkarni R. Multisite management study of menorrhagia with abnormal', 'laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral', 'tranexamic acid. Br J Haematol 2009; 145: 212-20.', '28.', 'Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Fressinaud E,', 'Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z,', 'Habart D, Holmberg L, Lethagan S, Pasi J, Hill F, Peake I. A quantitative analysis of bleeding', 'symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-', '1 VWD). J Thromb Haemost 2006; 4: 766-73.', '29.', 'Tosetto A, Castaman G, Rodeghiero F. Evidence-based diagnosis of type 1 von Willebrand disease:', 'A Bayes theorem approach. Blood 2008; 111: 3998-4003.', '30.', 'Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD. Menorrhagia', 'I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with', 'follow-up data. Am J Obstet Gynecol 2004; 190: 1216-23.', '31.', 'Mannucci PM. Desmopressin in the treatment of bleeding disorders: the first 20 years. Blood', '1997; 90: 2515-21.', '32.', 'Schlesinger KW, Rinder HM, Ragni MV. Women with bleeding disorders, in Menstrual Disorders,', \"eds., Ehrenthal DB, Hoffman MK, Hillard PJ, Women's Health Book Series, American College of\", 'Physicians/American Society of Internal Medicine, Philadelphia, 2006; 171-95.', '33.', 'Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. DDAVP nasal spray for treatment of', 'menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled', 'crossover study. Haemophilia 2002; 8: 787-93.', '34.', \"Lethagen S. Desmopressin in the treatment of women's bleeding disorders. Haemophilia 1999;\", '5:233-7.', '35.', 'Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. DDAVP nasal spray for treatment of', '53']\n\n###\n\n", "completion": "END"}